Prosight Management, LP Biocryst Pharmaceuticals Inc Transaction History

Prosight Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $4.14 Million - $6.8 Million	-1,001,300 Reduced 71.52%	398,700 $2.46 Million
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $4.07 Million - $6.37 Million	-832,242 Reduced 37.28%	1,400,000 $7.11 Million
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $875,947 - $1.19 Million	-175,893 Reduced 7.3%	2,232,242 $13.4 Million
Q3 2023 Nov 14, 2023	SELL	$6.71 - $7.92 $616,414 - $727,570	-91,865 Reduced 3.67%	2,408,135 $17 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $9.92 Million - $12.6 Million	1,425,407 Added 132.65%	2,500,000 $17.6 Million
Q1 2023 May 12, 2023	BUY	$7.94 - $11.84 $7.61 Million - $11.3 Million	957,861 Added 820.56%	1,074,593 $8.96 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $30,786 - $41,634	2,932 Added 2.58%	116,732 $1.34 Million
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $678,475 - $931,252	-62,880 Reduced 35.59%	113,800 $1.43 Million
Q2 2022 Aug 12, 2022	BUY	$7.89 - $17.88 $1.39 Million - $3.16 Million	176,680 New	176,680 $1.87 Million

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.